916325-83-2

Basic information

• Product Name: Methyl 1H-pyrazolo[3,4-b]pyridine-3-carboxylate
• Synonyms: Methyl 1H-pyrazolo[3,4-b]pyridine-3-carboxylate;Methyl 1H-pyrazolo[3,4-b]...;1H-Pyrazolo[3,4-b]pyridine-3-carboxylic acid, Methyl ester;Methyl 2H-pyrazolo[3,4-b]pyridine-3-carboxylate;pyrazolo[3,4-b]pyridine-3-carboxylic acid methyl ester
• CAS NO: 916325-83-2
• Molecular Formula: C₈H₇N₃O₂
• Molecular Weight: 177.162
• Mol File: 916325-83-2.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 362.9±22.0 °C(Predicted)
• Appearance: /
• Density: 1.403±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 7.85±0.40(Predicted)
• CAS DataBase Reference: Methyl 1H-pyrazolo[3,4-b]pyridine-3-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 1H-pyrazolo[3,4-b]pyridine-3-carboxylate(916325-83-2)
• EPA Substance Registry System: Methyl 1H-pyrazolo[3,4-b]pyridine-3-carboxylate(916325-83-2)

Safety Data

• Hazardous Substances Data: 916325-83-2(Hazardous Substances Data)

Usage

General Description

Methyl 1H-pyrazolo[3,4-b]pyridine-3-carboxylate is a chemical compound with the molecular formula C9H7N3O2. It is a derivative of pyrazolo[3,4-b]pyridine, which is a heterocyclic compound. This chemical is commonly used in the pharmaceutical industry as a building block for the synthesis of potential drug candidates. It has been studied for its potential therapeutic applications, including antitumor, antiviral, and antibacterial properties. Methyl 1H-pyrazolo[3,4-b]pyridine-3-carboxylate is important in medicinal chemistry and drug discovery efforts due to its potential pharmacological activities and its versatility in synthetic chemistry.

Upstream product

• 67-56-1 methanol 
• 201230-82-2 carbon monoxide 
• 117007-52-0 3-iodo-1H-pyrazolo[3,4-b]pyridine 
• 131674-39-0 2-chloro-3-(1-hydroxyethyl)pyridine 
• 116834-96-9 3-methyl-1H-pyrazolo[3,4b]pyridine 
• 109-09-1 2-chloropyridine 
• 55676-21-6 3-acetyl-2-chloropyridine 
• 116855-08-4 1H-pyrazolo[3,4-b]pyridine-3-carboxylic acid 

Downstream Products

• 1314734-68-3 1-(tetrahydro-2H-pyran-2-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazolo[3,4-b]pyridine-3-carbaldehyde 
• 916327-20-3 5-bromo-1H-pyrazolo[3,4-b]pyridine-3-carboxylic acid {2-amino-4-[2-(tert-butyl-dimethyl-silanyloxy)-ethoxy]-phenyl}-amide 
• 916326-42-6 5-bromo-1H-pyrazolo[3,4-b]pyridine-3-carboxylic acid [2-amino-3-(tert-butyl-dimethyl-silanyloxymethyl)-phenyl]-amide 
• 1314734-59-2 1-(tetrahydro-2H-pyran-2-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazolo[3,4-b]pyridine-3-carbaldehyde 

Relevant articles and documents

3-(3H-IMIDAZO[4,5-B]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINE AND THERAPEUTIC USES THEREOF

Azaindazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an azaindazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

ALKYNYL ALCOHOLS AND METHODS OF USE

The invention relates to compounds of Formula (0): wherein Q, A1-A8, R4 and R5 and each has the meaning as described herein. Compounds of Formula (0) and pharmaceutical compositions thereof are useful in the treatment of diseases and disorders in which undesired or over- activation of NF-kB signaling is observed.

LONIDAMINE ANALOGUES FOR FERTILITY MANAGEMENT

Fertility management can include: administering to the subject one or more doses of a compound according to Formula I so as to reduce fertility in the subject. Fertility management can also include administering an effective amount of the compound to: impair Sertoli cell function in a male subject; inhibit spermatogenesis in the subject; reduce testis weight in the subject; reduce ovary weight in a female subject; reduce serum progesterone in the female subject; impair ovarian follicle function in the female subject; causing reversible fertility in the subject. In order to return fertility, the method can include ceasing administration of the compound to the subject so as to return fertility in the subject. The compound can be administered for irreversibly sterilizing the subject.